» Articles » PMID: 25965345

Optimization of Invasion-Specific Effects of Betulin Derivatives on Prostate Cancer Cells Through Lead Development

Abstract

The anti-invasive and anti-proliferative effects of betulins and abietane derivatives was systematically tested using an organotypic model system of advanced, castration-resistant prostate cancers. A preliminary screen of the initial set of 93 compounds was performed in two-dimensional (2D) growth conditions using non-transformed prostate epithelial cells (EP156T), an androgen-sensitive prostate cancer cell line (LNCaP), and the castration-resistant, highly invasive cell line PC-3. The 25 most promising compounds were all betulin derivatives. These were selected for a focused secondary screen in three-dimensional (3D) growth conditions, with the goal to identify the most effective and specific anti-invasive compounds. Additional sensitivity and cytotoxicity tests were then performed using an extended cell line panel. The effects of these compounds on cell cycle progression, mitosis, proliferation and unspecific cytotoxicity, versus their ability to specifically interfere with cell motility and tumor cell invasion was addressed. To identify potential mechanisms of action and likely compound targets, multiplex profiling of compound effects on a panel of 43 human protein kinases was performed. These target de-convolution studies, combined with the phenotypic analyses of multicellular organoids in 3D models, revealed specific inhibition of AKT signaling linked to effects on the organization of the actin cytoskeleton as the most likely driver of altered cell morphology and motility.

Citing Articles

IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation.

Xu Y, Pachnikova G, Wang H, Wu Y, Przybilla D, Schafer R Bosn J Basic Med Sci. 2022; 22(4):580-592.

PMID: 35694767 PMC: 9392968. DOI: 10.17305/bjbms.2022.7279.


A clickable photoaffinity probe of betulinic acid identifies tropomyosin as a target.

Martin-Acosta P, Meng Q, Klimek J, Reddy A, David L, Petrie S Acta Pharm Sin B. 2022; 12(5):2406-2416.

PMID: 35646545 PMC: 9136574. DOI: 10.1016/j.apsb.2021.12.008.


Anti-Inflammatory and Anticancer Properties of Birch Bark-Derived Betulin: Recent Developments.

Tuli H, Sak K, Gupta D, Kaur G, Aggarwal D, Parashar N Plants (Basel). 2021; 10(12).

PMID: 34961132 PMC: 8705846. DOI: 10.3390/plants10122663.


Design and Synthesis of Novel Betulin Derivatives Containing Thio-/Semicarbazone Moieties as Apoptotic Inducers through Mitochindria-Related Pathways.

Wang J, Wu J, Han Y, Zhang J, Lin Y, Wang H Molecules. 2021; 26(21).

PMID: 34770765 PMC: 8587101. DOI: 10.3390/molecules26216356.


Chemical profiles of birch and alder bark by ambient mass spectrometry.

Rasanen R, Hieta J, Immanen J, Nieminen K, Haavikko R, Yli-Kauhaluoma J Anal Bioanal Chem. 2019; 411(28):7573-7583.

PMID: 31642944 PMC: 6875546. DOI: 10.1007/s00216-019-02171-9.


References
1.
Krausz E, De Hoogt R, Gustin E, Cornelissen F, Grand-Perret T, Janssen L . Translation of a tumor microenvironment mimicking 3D tumor growth co-culture assay platform to high-content screening. J Biomol Screen. 2012; 18(1):54-66. DOI: 10.1177/1087057112456874. View

2.
Harma V, Knuuttila M, Virtanen J, Mirtti T, Kohonen P, Kovanen P . Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models. Oncogene. 2011; 31(16):2075-89. PMC: 3330266. DOI: 10.1038/onc.2011.396. View

3.
Kola I, Landis J . Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov. 2004; 3(8):711-5. DOI: 10.1038/nrd1470. View

4.
Friedl P, Alexander S . Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011; 147(5):992-1009. DOI: 10.1016/j.cell.2011.11.016. View

5.
Shanmugam M, Manu K, Ong T, Ramachandran L, Surana R, Bist P . Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. Int J Cancer. 2011; 129(7):1552-63. DOI: 10.1002/ijc.26120. View